Minka Zivkovic

Minka Zivkovic

Auto-generated profile, based on publicly available information

Minka Zivkovic

Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Atherosclerosis
Verified
Journal Article
Open access
MSMax Silvis
Max Silvis
AFAernoud T.L. Fiolet
Aernoud T.L. Fiolet
TOTjerk S.J. Opstal
Tjerk S.J. Opstal
MDMirthe Dekker
Mirthe Dekker
DSDaniel Suquilanda
Daniel Suquilanda
DKDominique De Kleijn
Dominique De Kleijn
Colchicine reduces the risk of cardiovascular events in patients with coronary disease. Colchicine has broad anti-inflammatory effects and part of the atheroprotective effects have been suggested to be the result of NLRP3 inflammasome inhibition. We studied the effect of colchicine on extracellular vesicle (EV) NLRP3 protein levels and inflammatory markers, high sensitivity-CRP (hs-CRP) and interleukin (IL)-6, in patients with chronic coronary disease. In vitro, the NLRP3 inflammasome was stimulated in PMA-differentiated- and undifferentiated THP-1 cells. In vivo, measurements were performed in serum obtained from 278 participants of the LoDoCo2 trial, one year after randomization to colchicine 0.5 mg once daily or placebo. EVs were isolated using precipitation. NLRP3 protein presence in EVs was confirmed using iodixanol density gradient centrifugation. Levels of NLRP3 protein, hs-CRP and IL-6 were measured using ELISA. In vitro, NLRP3 inflammasome stimulation showed an increase of EV NLRP3 protein levels. EV NLRP3 protein levels were lower in patients treated with colchicine (median 1.38 ng/mL), compared to placebo (median 1.58 ng/mL) (p = 0.025). No difference was observed in serum NLRP3 protein levels. Serum hs-CRP levels were lower in patients treated with colchicine (median 0.80 mg/L) compared to placebo (median 1.34 mg/L) (p < 0.005). IL-6 levels were lower in patients treated with colchicine (median 2.07 ng/L) compared to placebo (median 2.59 ng/L), although this was not statistically significant (p = 0.076). Colchicine leads to a reduction of EV NLRP3 protein levels. This indicates that inhibitory effects on the NLRP3 inflammasome might contribute to the atheroprotective effects of colchicine in coronary disease.

8 February 2024 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
PGPrafull S. Gandhi
Prafull S. Gandhi
MZMinka Zivkovic
Minka Zivkovic
HØHenrik Østergaard
Henrik Østergaard
ABAmalie C. Bonde
Amalie C. Bonde
TETorben Elm
Torben Elm
JFJohan H. Faber
Johan H. Faber
Inherited bleeding disorders such as Glanzmann thrombasthenia (GT) lack prophylactic treatment options. As a result, serious bleeding episodes are treated acutely with blood product transfusions or frequent, repeated intravenous administration of recombinant activated coagulation factor VII (rFVIIa). Here we describe HMB-001, a bispecific antibody designed to bind and accumulate endogenous FVIIa and deliver it to sites of vascular injury by targeting it to the TREM (triggering receptor expressed on myeloid cells)-like transcript-1 (TLT-1) receptor that is selectively expressed on activated platelets. In healthy nonhuman primates, HMB-001 prolonged the half-life of endogenous FVIIa, resulting in its accumulation. Mouse bleeding studies confirmed antibody-mediated potentiation of FVIIa hemostatic activity by TLT-1 targeting. In ex vivo models of GT, HMB-001 localized FVIIa on activated platelets and potentiated fibrin-dependent platelet aggregation. Taken together, these results indicate that HMB-001 has the potential to offer subcutaneous prophylactic treatment to prevent bleeds in people with GT and other inherited bleeding disorders, with a low-frequency dosing regimen.

15 October 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
WSWariya Sanrattana
Wariya Sanrattana
SSSimone Smits
Simone Smits
ABArjan Barendrecht
Arjan Barendrecht
NKNadine Denise van Kleef
Nadine Denise van Kleef
HOHinde El Otmani
Hinde El Otmani
CMCoen Maas
Coen Maas
Background Occlusive thrombi are not homogeneous in composition. The core of a thrombus is rich in activated platelets and fibrin while the outer shell contains resting platelets. This core is inaccessible to plasma proteins. We produced a fusion protein (targeted SERPIN – TaSER), consisting of a function-blocking VHH against glycoprotein Ibα and a thrombin-inhibiting serine protease inhibitor (SERPIN; α1-antitrypsin 355AIAR358) to interfere with platelet-driven thrombin formation. Aim To evaluate the antithrombotic properties of TaSER. Methods Besides TaSER, we generated three analogous control variants with either a wild-type antitrypsin subunit, a non-targeting control VHH, or their combination. We investigated TaSER and controls in protease activity assays, (platelet-dependent) thrombin generation assays and by western blotting. The effects of TaSER on platelet activation and von Willebrand Factor (VWF)-binding were studied by FACS, in agglutination studies and in ATP secretion experiments. We studied the influence of TaSER in whole blood 1) on platelet adhesion on VWF, 2) aggregate formation on collagen and 3) thrombus formation (after recalcification) on collagen and tissue-factor. Results TaSER binds platelets and inhibits thrombin activity on the platelet surface. It blocks VWF binding and disassembles platelet agglutinates. TaSER delays tissue factor-triggered thrombin generation and ATP secretion in platelet-rich plasma in a targeted manner. In flow studies, TaSER interferes with platelet adhesion and aggregate formation due to GPIbα blockade and limits thrombus formation due to targeted inhibition of platelet-dependent thrombin activity. Conclusion The synergy between the individual properties of TaSER makes it a highly effective antithrombotic agent with possible clinical implications.

14 April 2026 in Blood Advances
Verified
Journal Article
Open access
MHMattias Häger
Mattias Häger
MZMinka Zivkovic
Minka Zivkovic
PGPrafull S. Gandhi
Prafull S. Gandhi
CRCaroline Rasmussen
Caroline Rasmussen
CBCécile Bonvoisin
Cécile Bonvoisin
HØHenrik Østergaard
Henrik Østergaard
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, resulting from deficiency or dysfunction of von Willebrand factor (VWF), a protein crucial for hemostasis. Current prophylactic options present significant limitations including poor tolerability, short half-life, or the requirement for frequent IV administration. Here, we report HMB-002, a human Fc-silenced monovalent IgG4 antibody designed to provide convenient subcutaneous prophylaxis by binding and elevating levels of endogenous VWF. Binding studies and X-ray crystallography revealed that HMB-002 binds VWF with subnanomolar affinity at a well-defined epitope in the C-terminal cysteine-knot (CK) domain, which is spatially distant from regions mediating VWF’s hemostatic functions. Consistent with structural analyses, in vitro functional studies demonstrated that HMB-002-bound VWF retained its ability to bind factor VIII (FVIII), platelet GPIbα, and collagen, as well as susceptibility to proteolytic regulation by ADAMTS13. In cynomolgus monkeys, IV and subcutaneous administration of HMB-002 resulted in time-dependent accumulation of endogenous VWF and FVIII antigen, reaching about twofold elevation with a proportional increase in VWF activity and with retained VWF multimer distribution. HMB-002 also extended the half-life of coadministered recombinant VWF by approximately threefold. Using a surrogate antibody with overlapping epitope specificity, similar VWF accumulation was observed in a type 1 VWD mouse model with improved hemostasis following vascular challenge. By elevating levels of circulating VWF and FVIII, HMB-002 represents a potential subcutaneous prophylactic treatment approach to mitigate the hemostatic impairment in VWD and address current limitations in disease management.